CrushSCI.com
206.5Average days
220.5Median days
127Fastest days
276Longest days
862025 publications

Paper Review Records

All Paper Review Records

6 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.

276 days

A multi-platform analysis of paired well- and dedifferentiated liposarcoma identifies recurrent genomic alterations associated with progression and recurrence

Authors
Aimee M. Crago; Alexander Lofthus; Amanda Craig; Jia Hu; Rachael O'Connor; Penelope D. Ruiz; Winan J. van Houdt; Lakshana Senthilkumar; Tomoyo Okada; Tianjie Pu; Kalyani Chadalavada; Nils Weinhold; Cyriac Kandoth; Phaedra Agius; Agnes Viale; Li-Xuan Qin; Cristina R. Antonescu; Nicholas D. Socci; Samuel SingerShow moreShow less
Affiliations
1. Memorial Sloan Kettering Cancer Center 1 New York, NY; 2. National Institutes of Health 2 Bethesda, MD; 3. Rockefeller University 3 New York City; 4. The Netherlands Cancer Institute 4 Amsterdam; 5. Memorial Sloan Kettering Cancer Center 5 New York; 6. University of Pennsylvania 6 Philadelphia, PennsylvaniaShow moreShow less
Source PDF DOI Publisher page
127 days

Integrative Surface Antigen Profiling of KLK2 and STEAP1 in Advanced Prostate Cancer

Authors
Erolcan Sayar; Helen M. Richards; Roman Gulati; Radhika A. Patel; Brian Hanratty; Hyun Jung Lee; Ilsa Coleman; Pallabi Mustafi; Chien-Kuang Cornelia Ding; William S. Chen; David Quigley; Manu Setty; Joshua M. Lang; Lawrence D. True; Lori Kollath; Daniel W. Lin; Jun Luo; John K. Lee; Gavin Ha; Evan Y. Yu; Heather H. Cheng; Bruce Montgomery; Eva Corey; Colm Morrissey; Michael T. Schweizer; Peter S. Nelson; Ruben Raychaudhuri; Michael C. HaffnerShow moreShow less
Affiliations
1. Fred Hutchinson Cancer Center 1 Division of Human Biology, , Seattle, Washington.; 2. Fred Hutchinson Cancer Center 2 Division of Public Health Sciences, , Seattle, Washington.; 3. University of Washington 3 Department of Laboratory Medicine and Pathology, , Seattle, Washington.; 4. 4Department of Pathology, Pusan National University School of Medicine, Yangsan, Korea.; 5. 5Pusan National University Yangsan Hospital, Yangsan, Korea.; 6. University of California San Francisco 6 Department of Anatomic Pathology, , San Francisco, California.; 7. 7UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California.; 8. University of California San Francisco 8 Department of Urology, , San Francisco, California.; 9. University of California San Francisco 9 Department of Radiation Oncology, , San Francisco, California.; 10. University of California San Francisco 10 Department of Epidemiology and Biostatistics, , San Francisco, California.; 11. Fred Hutchinson Cancer Center 11 Basic Sciences Division, , Seattle, Washington.; 12. Fred Hutchinson Cancer Center 12 Translational Data Science IRC, , Seattle, Washington.; 13. University of Wisconsin-Madison 13 , Madison, Wisconsin.; 14. University of Washington 14 Department of Urology, , Seattle, Washington.; 15. 15James Buchanan Brady Urological Institute, Johns Hopkins School of Medicine, Baltimore, Maryland.; 16. 16Division of Hematology and Oncology, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California.; 17. 17Parker Institute for Cancer Immunotherapy at UCLA, Los Angeles, California.; 18. Fred Hutchinson Cancer Center 18 Clinical Research Division, , Seattle, Washington.; 19. University of Washington 19 Division of Hematology and Oncology, Department of Medicine, , Seattle, Washington.Show moreShow less
Source PDF DOI Publisher page
127 days

Variation at the R181 Residue of p53 Confers Loss of p53 DNA Binding Cooperativity with the Retention of Mitochondria-Associated Apoptosis

Authors
Renyta Moses; Alexandra Indeglia; Alison S. Levine; Ryan Hausler; Gregory Kelly; Sven A. Miller; Isabel Anez; Melissa Heller; Rosella Delgado; Caitlin Orr; Wendy Kohlmann; Anne Naumer; Jennie Vagher; Sophie R. Cahill; Luke D. Maese; John Karanicolas; Judy E. Garber; Maureen E. Murphy; Kara N. MaxwellShow moreShow less
Affiliations
1. University of Pennsylvania 1 Department of Medicine, Division of Hematology-Oncology, Perelman School of Medicine, , Philadelphia, Pennsylvania.; 2. University of Pennsylvania 2 Graduate Group in Cell and Molecular Biology, Perelman School of Medicine, , Philadelphia, Pennsylvania.; 3. University of Pennsylvania 3 Graduate Group in Biochemistry and Molecular Biophysics, Perelman School of Medicine, , Philadelphia, Pennsylvania.; 4. 4Program in Molecular and Cellular Oncogenesis, Wistar Institute, Philadelphia, Pennsylvania.; 5. Dana-Farber Cancer Institute 5 , Harvard Medical School, Boston, Massachusetts.; 6. Fox Chase Cancer Center 6 Cancer Signaling and Microenvironment Program, , Philadelphia, Pennsylvania.; 7. Huntsman Cancer Institute 7 , , Primary Children's Hospital, Salt Lake City, Utah.; 8. University of Utah 7 , , Primary Children's Hospital, Salt Lake City, Utah.; 9. University of Pennsylvania 8 Abramson Cancer Center, Perelman School of Medicine, , Philadelphia, Pennsylvania.Show moreShow less
Source PDF DOI Publisher page
203 days

Archetype Analysis of Lung Adenocarcinoma Premalignancy Links Heterogeneity in Premalignant Lesions to Diverging Features of Invasive Disease

Authors
Kelley E. Anderson; Linh M. Tran; Kostyantyn Krysan; Yohana Kefella; Lingge Yu; Gregory A. Fishbein; Erika F. Rodriguez; Maryam Shabihkhani; Daniel P. Stefanko; Emily Green; Gang Liu; Hanqiao Liu; Sherry Zhang; Erin Kane; Mitra Mehrad; Avrum E. Spira; Steven M. Dubinett; Eric J. Burks; Sarah A. Mazzilli; Marc E. Lenburg; Jennifer E. BeaneShow moreShow less
Affiliations
1. 1Section of Computational Biomedicine, Boston University Chobanian and Avedisian School of Medicine, Boston, Massachusetts.; 2. 2Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California.; 3. 3Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California.; 4. Vanderbilt University Medical Center 4 Department of Pathology, Microbiology, and Immunology, , Nashville, Tennessee.; 5. 5Department of Pathology, Boston University Chobanian and Avedisian School of Medicine, Boston, Massachusetts.Show moreShow less
Source PDF DOI Publisher page
238 days

Mapping the Subtype-Specific PARP1 ADP-Ribosylated Proteome in Breast Cancer Cells

Authors
Sneh Koul; Minjung Kwon; Poulami Tapadar; Yangyang Dai; Weidan Song; Morgan Dasovich; Tulip Nandu; Dan Huang; Cristel V. Camacho; W. Lee KrausShow moreShow less
Affiliations
1. 1Laboratory of Signaling and Gene Regulation, Cecil H. and Ida Green Center for Reproductive Biology Sciences, University of Texas Southwestern Medical Center, Dallas, Texas.; 2. 2Computational Core Facility, Cecil H. and Ida Green Center for Reproductive Biology Sciences, University of Texas Southwestern Medical Center, Dallas, Texas.; 3. 3Section of Basic Research, Department of Obstetrics and Gynecology, University of Texas Southwestern Medical Center, Dallas, Texas.Show moreShow less
Source PDF DOI Publisher page
268 days

Ceramide-Induced Endoplasmic Reticulum Stress Reveals a Targetable Vulnerability in Endocrine Therapy–Resistant Breast Cancer

Authors
Purab Pal; Shweta Chitkara; Godwin K. Sarpey; Aanshi Vashi; Vipin Rawat; Fatimah Alani; Huiping Zhao; Malik Ata; Jun Qu; Rachel Schiff; Debra Tonetti; Geoffrey L. Greene; Jonna Frasor; Gunes Ekin Atilla-Gokcumen; Jonathan L. ColoffShow moreShow less
Affiliations
1. University of Illinois Chicago 1 Department of Physiology and Biophysics, , Chicago, Illinois.; 2. University at Buffalo 2 Department of Chemistry, , Buffalo, New York.; 3. University of Illinois Chicago 3 College of Medicine, , Chicago, Illinois.; 4. University at Buffalo 4 Department of Pharmaceutical Sciences, , Buffalo, New York.; 5. Baylor College of Medicine 5 Lester and Sue Smith Breast Center, , Houston, Texas.; 6. University of Illinois Chicago 6 Department of Pharmaceutical Sciences, , Chicago, Illinois.; 7. University of Chicago 7 Ben May Department for Cancer Research, , Chicago, Illinois.Show moreShow less
Source PDF DOI Publisher page

FAQ

How long does MOLECULAR CANCER RESEARCH take to review a manuscript?

As of 2026-11-19, CrushSCI has 6 complete review records for MOLECULAR CANCER RESEARCH. The fastest paper went from submission to acceptance in 127 days (Integrative Surface Antigen Profiling of KLK2 and STEAP1 in Advanced Prostate Cancer, received 2026-01-14, accepted 2026-05-21); the slowest took 276 days. The average is 206.5 days and the median is 220.5 days.

Expert Matching · Case Demo

Turn Your Submission Goalsinto a Verifiable Journal Plan

Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.

We will reply within 30 minutes.

CrushSCI online

Client

I work in environmental engineering and need an SCI paper published within three months. I have no grant funding or prominent co-author. Which journals could I target?

CrushSCI

Yes. We will first screen for feasibility against the 90-day deadline, then identify comparable papers without grant support or prominent co-authors. The final shortlist will prioritize research quality and journal scope.

Suggested title
Machine Learning and Life-Cycle Assessment for Predicting and Optimizing Carbon Emissions in Urban Wastewater Treatment

SampleLatest 5 valid paper samples from 2026

Average review59.6 days

Median65 days

Contact CrushSCI

Contact CrushSCI

Leave your email address to discuss academic polishing, structural refinement, or one-to-one guidance.

We will reply within 30 minutes.

Selected service: Academic Consulting Service

Leave your email address

Or email us directly at leader@crushsci.com

Enter your email address so we can reply. Your details will remain private.